All Stories

  1. Letrozole Reduces Ovulatory Responsiveness in In Vitro‐Grown Mouse Follicles
  2. Comparison of the efficacy and safety of five-day methotrexate versus pulse actinomycin D for low-risk gestational trophoblastic neoplasia: a single-center historical cohort study☆
  3. Response to the Correspondence by Xu, et al. regarding "Comparison of the efficacy and safety of five-day methotrexate versus pulse actinomycin D for low-risk gestational trophoblastic neoplasia"
  4. Response to the Correspondence by Fang Q. regarding "Comparison of the efficacy and safety of five-day methotrexate versus pulse actinomycin D for low-risk gestational trophoblastic neoplasia"
  5. Evaluation of the usefulness of sentinel lymph node mapping using indocyanine green in patients with cervical and endometrial cancers: A single‐center prospective exploratory study
  6. Resolution of pelvic postoperative spindle cell nodule with sarcomatous onset after 9 years of follow‐up
  7. A phantom human chorionic gonadotropin in the case of molar pregnancy
  8. Therapy‐related myeloid neoplasms after treatment for ovarian cancer: A retrospective single‐center case series
  9. Single‐nucleotide polymorphism array and fluorescence in situ hybridization analysis to decode the cytogenetic profile of atypical partial hydatidiform moles diagnosed by short tandem repeat polymorphism analysis
  10. Evaluation of Combined p57KIP2 Immunohistochemistry and Fluorescent in situ Hybridization Analysis for Hydatidiform Moles Compared with Genotyping Diagnosis
  11. Letter to the editor on Donzel M et al. “Androgenetic/biparental mosaicism in a diploid mole-like conceptus: report of a case with triple paternal contribution”
  12. Total human chorionic gonadotropin is a more suitable diagnostic marker of gestational trophoblastic diseases than the free β-subunit of human chorionic gonadotropin
  13. A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results
  14. Prognosis prediction of uterine cervical cancer using changes in the histogram and texture features of apparent diffusion coefficient during definitive chemoradiotherapy
  15. Suppressor‐type TERT mutations associated with recurrence in ovarian clear cell carcinoma
  16. Delayed postrenal failure due to progression of asymptomatic hydronephrosis following hysterectomy
  17. Auxiliary and experimental diagnostic techniques for hydatidiform moles
  18. Short tandem repeat polymorphism analysis for primary peritoneal choriocarcinoma: A case report and literature review
  19. Discrepancies in pathological diagnosis of endometrial stromal sarcoma: a multi-institutional retrospective study from the Japanese clinical oncology group
  20. The effect of steep head-down tilt on respiratory status in endometrial cancer patients with obesity during robot-assisted hysterectomy
  21. Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study
  22. High prevalence of pulmonary embolism prior to cancer therapies in patients with ovarian and endometrial cancers detected by contrast‐enhanced CT using D‐dimer as an index
  23. Spermatogonium-Derived Complete Hydatidiform Mole
  24. Surgical margin status and recurrence pattern in invasive vulvar Paget’s disease: A Japanese Gynecologic Oncology Group study
  25. Placenta accreta after remission of low-risk gestational trophoblastic neoplasia: A case report
  26. Parental contribution to trisomy in heterozygous androgenetic complete moles
  27. Androgenetic Complete Hydatidiform Moles With p57KIP2-Positive Immunostaining
  28. ABO blood type compatibility is not a risk factor for gestational trophoblastic neoplasia development from androgenetic complete hydatidiform moles
  29. Second Uterine Curettage and the Number of Chemotherapy Courses in Postmolar Gestational Trophoblastic Neoplasia
  30. Comparison between vacuum aspiration and forceps plus blunt curettage for the evacuation of complete hydatidiform moles
  31. IFPA meeting 2018 workshop report II: Abnormally invasive placenta; inflammation and infection; preeclampsia; gestational trophoblastic disease and drug delivery
  32. Genome-wide single nucleotide polymorphism array analysis unveils the origin of heterozygous androgenetic complete moles
  33. Radiation Therapy for Extrapelvic Lymph Node Recurrence After Curative Treatment for Cervical Cancer
  34. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
  35. Variant Prolactin Receptor in Agalactia and Hyperprolactinemia
  36. Response to Letter to ‘Removal of retained products of conception showing marked vascularity without uterine artery embolization: Two case reports’
  37. Gestational Trophoblastic Neoplasia From Genetically Confirmed Hydatidiform Moles: Prospective Observational Cohort Study
  38. Bacterial-Culture-Negative Subclinical Intra-Amniotic Infection Can Be Detected by Bacterial 16S Ribosomal-DNA–Amplifying Polymerase Chain Reaction
  39. Removal of retained products of conception showing marked vascularity without uterine artery embolization: Two case reports
  40. Elucidation of the developmental mechanism of ovarian mature cystic teratomas using B allele-frequency plots of single nucleotide polymorphism array data
  41. Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide
  42. ADJUVANT CHEMOTHERAPY MAY NOT BE NECESSARY FOR LOW-INTERMEDIATE RISK ENDOMETRIAL CANCER
  43. Complete hydatidiform moles are composed of paternal chromosomes and maternal mitochondria
  44. The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer
  45. Presence of the methylenetetrahydrofolate reductase gene polymorphism MTHFR C677T in molar tissue but not maternal blood predicts failure of methotrexate treatment for low-risk gestational trophoblastic neoplasia
  46. A case report and review of the literature: 3 infants of umbilical cord ulcerations associated with polyhydramnios
  47. Postoperative Radiation Therapy for Cervical Cancer: Three-Dimensional Conformal Radiation Therapy (3DCRT) Versus Intensity Modulated Radiation Therapy (IMRT)
  48. Ovarian nongestational choriocarcinoma and associated adenocarcinoma with the same germ cell origin determined by a molecular genetic approach: A case report
  49. Local injection of diluent vasopressin followed by suction curettage as initial treatment of cervical ectopic pregnancy
  50. Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study
  51. Mature cystic teratomas arise from meiotic oocytes, but not from pre-meiotic oogonia
  52. Comparison of 5-day MTX and 5-day ETP treatment results and early predictors of drug resistance to 5-day MTX in patients with post-molar low-risk gestational trophoblastic neoplasia
  53. Early pregnancy-associated cardiomyopathy complicated with a complete hydatidiform mole coexistent with a live fetus and exacerbated by induced abortion
  54. Three point mutations of promoter I.1 of marmoset aromatase gives rise of human type exonI.1
  55. Tubal pregnancy associated with additional conception in a contralateral tube
  56. The Clinical Characteristics and Early Detection of Postpartum Choriocarcinoma
  57. Daily Low-Dose Cisplatin-Based Concurrent Chemoradiotherapy for the Treatment of Cervical Cancer in Patients 70 Years or Older
  58. The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer
  59. EARLY ONSET PERIPARTUM CARDIOMYOPATHY FOLLOWING DILATION AND EVACUATION FOR COMPLETE HYDATIDIFORM MOLE COEXISTENT WITH LIVE FETUS
  60. Regulation of expression of p57KIP2 gene in extravillous trophoblast cells
  61. A phase II study of medroxyprogesterone acetate plus metformin as fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
  62. Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma
  63. A case of vanishing partial hydatidiform mole coexistent with a live fetus (HMCF)
  64. Daily Low-Dose Cisplatin-Based Concurrent Chemoradiotherapy in Patients With Uterine Cervical Cancer With Emphasis on Elderly Patients
  65. Outcomes of Concurrent Chemoradiation Therapy for Neuroendocrine Carcinoma of Cervix
  66. Revaluation of cytogenetic diagnosis of partial hydatidiform moles by short tandem repeats polymorphism analysis
  67. Numerous psammoma bodies in cervical cytology of high‐grade endocervical adenocarcinoma
  68. IFPA Meeting 2012 Workshop Report III: Trophoblast deportation, gestational trophoblastic disease, placental insufficiency and fetal growth restriction, trophoblast over-invasion and accreta-related pathologies, placental thrombosis and fibrinolysis
  69. Expression of Angiotensin II Receptor-like 1 in the Placentas of Pregnancy-induced Hypertension
  70. The effect of metformin on cell proliferation in patients with endometrial cancer.
  71. Molecular Distinction of Consecutive Molar Pregnancies
  72. The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles
  73. High Aromatase Expression in Uterine Leiomyoma Tissues of African-American Women
  74. Serum YKL-40 as a marker for cervical adenocarcinoma
  75. Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix
  76. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis
  77. Serum YKL-40 levels are usuful diagnostic tumor markers for adenocarcinoma of the uterine cervix